Acrivon Therapeutics, Inc. (ACRV) vs Rallybio Corporation (RLYB)

Acrivon Therapeutics, Inc. and Rallybio Corporation are both Biotechnology companies. Acrivon Therapeutics, Inc. and Rallybio Corporation are of similar size ($90.9M and $88.2M). Acrivon Therapeutics, Inc. has negative trailing earnings, so its P/E is not meaningful; Rallybio Corporation trades at 2.1×. Across the 10 metrics below, Rallybio Corporation leads on 8 and Acrivon Therapeutics, Inc. on 2.

Valuation

Metric ACRV RLYB Biotechnology median
P/E n/m 2.06 7.88
P/S n/m 110.39 11.47
P/B 1.01 1.00 2.52
Price to free cash flow n/m 3.55 21.16
EV/EBITDA 0.03 n/m 0.74
EV/Sales n/m 2.18 10.73
Earnings yield (89.52%) 48.49% (28.84%)
Free cash flow yield (72.99%) 28.17% (23.03%)

Profitability

Metric ACRV RLYB Biotechnology median
Gross margin 0.00% 100.00% 65.16%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (64.63%) 64.86% (57.72%)
Return on assets (57.61%) 61.12% (49.22%)
Return on invested capital 0.00% (1,052.03%) 0.00%

Growth

Metric ACRV RLYB Biotechnology median
Revenue growth (TTM) — 1.18% 5.64%
EPS growth (last fiscal year) 15.13% 85.06% —
Revenue growth, 5-year CAGR — — 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric ACRV RLYB Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 7.99 27.26 4.73
Net debt to EBITDA 1.43 1.63 0.96

Dividend

Metric ACRV RLYB Biotechnology median
Dividend yield — — 2.10%
Payout ratio — 0.00 0.00

Size

Metric ACRV RLYB Biotechnology median
Market cap 90.85m 88.21m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack